Webcast

Test Your Knowledge: An Interactive Session on Emerging Data and Expert Insights on Hepatitis B

Launch Date
04/07/2021
Credit Amount
0.00 Expired
Credit Expires
04/07/2022

Faculty

Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD
Director, Liver Institute Northwest
Clinical Professor, Elson S. Floyd College of Medicine, Washington State University, Seattle, WA
Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD

Dr. Kowdley received his BS in Biology and Anthropology as a member of the Dean’s List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine.

Dr. Kowdley is internationally recognized as a clinician, educator, and researcher in the area of liver disease and has presented his research on liver diseases at more than 165 national and international meetings and scientific symposia. He is the author of over 450 articles, book chapters, reviews, and commentaries in this area, with publications in the Annals of Internal Medicine, Archives of Surgery, Gastroenterology, Hepatology, American Journal of Physiology, and New England Journal of Medicine, among other professional publications.

Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, including hepatitis C, cholestatic liver disease, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), nonalcoholic steatohepatitis, and hepatitis B. He has been a principal investigator in several NIDDK-sponsored clinical trials in PBC and PSC and is a member of executive committee of the nonalcoholic steatohepatitis clinical research network (NASH CRN). Dr. Kowdley has also served as the lead investigator of several major international clinical trials in hepatitis C.

Dr. Kowdley’s laboratory program is focused on the role of iron as a co-factor in many liver diseases, including hepatitis C, hemochromatosis, and nonalcoholic steatohepatitis (NASH). He has developed murine models for NASH and is currently exploring the contribution of hepatic iron deposition on the severity of NASH.

Dr. Kowdley’s research program has been continuously funded by the NIDDK since 1999 in addition to several grants from foundations and scientific societies.

Joseph K. Lim, MD
Professor of Medicine
Director, Clinical Hepatology
Vice-Chief, Section of Digestive Diseases Yale University School of Medicine New Haven, CT
Joseph K. Lim, MD

Dr. Lim is a Professor of Medicine and Vice-Chief of the Section of Digestive Diseases at Yale University, where he serves as Director of Clinical Hepatology and Associate Chief of Yale-New Haven Health System (YNHHS) Digestive Health. He is a graduate of the Feinberg School of Medicine at Northwestern University (Chicago, Illinois, USA), and completed training in Internal Medicine at Yale University (New Haven, Connecticut, USA), and Gastroenterology and Hepatology at Stanford University (Palo Alto, California, USA). In his role at the Yale Liver Center, he conducts patient-oriented research evaluating clinical outcomes in chronic liver disease and runs an active clinical trials program examining novel investigational agents for viral hepatitis and NASH. He has held numerous leadership roles for the AASLD, AGA, and the ACG, and serves as Chair of the EPIC Gastroenterology Specialty Steering Board.

Grace M. Wang, MD, MPH, FAAFP
Family Physician, International Community Health Services
Clinical Instructor, Department of Medicine, University of Washington School of Medicine, Seattle, WA
Grace M. Wang, MD, MPH, FAAFP

Dr. Grace Wang is a board-certified family physician at International Community Health Services, a federally qualified health center in Seattle, Washington. Dr. Wang graduated from the University of Michigan with a degree in Early Childhood Education. She received her medical training at Cornell University Medical College (now Weill Cornell Medicine) in New York City and has a master’s degree in public health, also from the University of Michigan. Dr. Wang has worked in primary care and public health in New York City and Seattle.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credits

Statement of Need

Chronic hepatitis B (HBV) imposes a significant disease burden and identifying those at-risk for HBV is imperative to implementing effective care. More than half of people living with HBV are of Asian, Pacific Islander, or African descent, and HBV and the resulting hepatocellular cancer (HCC) contribute to substantial health disparities for these groups. While HBV is not curable, early detection, treatment, and monitoring can reduce the risk of liver disease and HCC.

Test your knowledge during this interactive CME Outfitters Live and OnDemand webcast featuring augmented reality animations that will reinforce the fibrotic consequence of untreated HBV. Data presentation and translation will showcase the importance of implementing routine screening protocols, optimizing efficacy and safety profiles of current agents when initiating or switching treatment, and routinely monitoring patients with HBV for disease progression HCC, and HBV reactivation.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Implement routine screening protocols for HBV in the primary care setting to derive guideline-directed care.
  • Optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV.
  • Routinely monitor patients with HBV every 6 months for disease progression, HCC, and HBV reactivation in patients who are immunosuppressed.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Explain routine screening protocols for HBV in the primary care setting to derive guideline-directed care.
  • Summarize efficacy and safety profiles of current agents for the treatment of HBV.
  • Describe how to routinely monitor patients with HBV every 6 months for disease progression, HCC, and HBV reactivation in patients who are immunosuppressed.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, nurse practitioners, PAs, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kowdley reports that he receives research support from Janssen Pharmaceuticals, Inc. He is on the speakers bureau for Gilead Sciences, Inc. He is a consultant for Altimmune.

Dr. Lim reports he received research support from Allergan; Celgene Corporation; Eiger BioPharmaceuticals; GENFIT; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.

Dr. Wang has no disclosures to report.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Noreen Iftikhar, MD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-032-H01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 

TV-126-040721-47

 

Test Your Knowledge: An Interactive Session on Emerging Data and Expert Insights on Hepatitis B
Event Date: 04/07/2021